Efficacy and safety of ligelizumab in adults and adolescents with chronic spontaneous urticaria: results of two phase 3 randomised controlled trials
Novartis Pharmaceuticals
Marcus Maurer; Luis Felipe Ensina; Ana Maria Gimenez-Arnau; Gordon Sussman; Michihiro Hide; Sarbjit Saini; Clive Grattan; Daria Fomina; Dimitrios Rigopoulos; Frederic Berard; Giorgio Walter Canonica; Heike Rockmann; Carla Irani; Jacek C Szepietowski; Jeffrey Leflein; Jonathan A Bernstein; Jonny G Peter; Kanokvalai Kulthanan; Kiran Godse; Ledit Ardusso; Olga Ukhanova; Petra Staubach; Rodney Sinclair; Shaila Gogate; Simon Francis Thomsen; Tonny Tanus; Young Min Ye; Alis Burciu; Avantika Barve; Darshna Modi; Emil Scosyrev; Eva Hua; Kerstin Letzelter; Vineeth Varanasi; Manmath Patekar; Thomas Severin; PEARL-1 and PEARL-2 trial investigators